FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL										
	OMB Number:	3235-0287									
l	Estimated average b	urden									

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Fair Brett  (Last) (First) (Middle)  C/O ACLARIS THERAPEUTICS, INC.						Issuer Name and Ticker or Trading Symbol     Aclaris Therapeutics, Inc. [ ACRS ]      Date of Earliest Transaction (Month/Day/Year)     02/01/2019											ationship of Reporting k all applicable) Director Officer (give title below) Chief Commo			10% Ov Other (s below)	ner	
640 LEE ROAD, SUITE 200  (Street) WAYNE PA 19087  (City) (State) (Zip)						4. If Amendment, Date of Original Filed (Month/Day/Year)										Indivi ne) X						
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																						
1. Title of Security (Instr. 3)  2. Transac Date (Month/Da					Executi			Code (Instr.						4 and Secu Bene Own		es ally Following	Form (D) o	n: Direct r Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership			
									Cod	e v		Amount	nt (A) or		Price	- 1	Reported Transact (Instr. 3	ction(s)			(Instr. 4)	
Common Stock 02/01/						2019			М			3,875	'5 A		(1)		11,890		D			
Common Stock 02/01/												1,308	08 D		\$6.9	96	10,582		D			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	Date,		ansaction ode (Instr.		of		6. Date Exercisal Expiration Date (Month/Day/Year			7. Title and Amount of Securities Underlying Derivative Secur (Instr. 3 and 4)			Der Sec	Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Ow For Dir or (I)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Co	Code	v	(A)		Date Exercis	able	Ex Da	piration te	Title		Amount or Number of Shares							
Restricted Stock	(1)	02/01/2019			M			3,875	(3)			(3)	Com	nmon ock	3,875	\$	0.00	11,625	,	D		

## **Explanation of Responses:**

- 1. Restricted stock units convert into common stock on a one-for-one basis.
- 2. The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4.
- 3. The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.

## Remarks:

/s/ Mark Ballantyne, Attorneyin-fact 02/05/2019

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.